Lymphoma: all 5,624 studies
Page 30 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and LymphomaCompletedNCT03934814Phase 1
- A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaActive, not recruitingNCT03934567Phase 2
- Strength Training and ADLs in Childhood Leukemia and Lymphoma PatientsCompletedNCT03934060Not applicable
- MC-19PD1 CAR-T in Relapsed or Refractory B Cell LymphomaStatus unknownNCT03932955Phase 1
- A Metagenome-wide Association Study of Gut Microbiota in Gastrointestinal Non-Hodgkin's Lymphoma PatientsStatus unknownNCT03930043
- Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.Status unknownNCT03929107Phase 2
- Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell TransplantationCompletedNCT03925935Phase 1
- Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
- Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing TxCompletedNCT03923504Not applicable
- Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory LymphomaStatus unknownNCT03921879Phase 1
- Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell LymphomasWithdrawnNCT03920631Phase 1
- Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell TherapyStatus unknownNCT03910842Early Phase 1
- A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT03900598Phase 1
- Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat LymphomaCompletedNCT03900377Phase 1/2
- ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and LymphomaStatus unknownNCT03895944Early Phase 1
- A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's LymphomasTerminatedNCT03893682Phase 1
- Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell LymphomaTerminatedNCT03892525Phase 1
- Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT03892421Phase 1/2
- Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaCompletedNCT03892044Phase 1
- Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCLStatus unknownNCT03891355Phase 2
- Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)WithdrawnNCT03888534Phase 1
- A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic MalignanciesCompletedNCT03886831Phase 1
- Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.TerminatedNCT03886649Phase 1
- VPA Expanded UCB Transplantation for Treatment of Patients With Hematological MalignanciesCompletedNCT03885947Phase 1
- Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK InhibitorWithdrawnNCT03884972Phase 1
- Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell MalignanciesStatus unknownNCT03881774Phase 1
- CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell LymphomaStatus unknownNCT03881761Phase 1
- Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell LymphomaWithdrawnNCT03880279Phase 1/2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma PatientsTerminatedNCT03876028Phase 1
- A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT03873025Phase 1/2
- Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)CompletedNCT03870945Phase 1
- Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma PatientsStatus unknownNCT03870412Not applicable
- Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaTerminatedNCT03864419Phase 1
- Ex Vivo Drug Sensitivity Testing and Mutation ProfilingCompletedNCT03860376
- Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular)Status unknownNCT03859544
- CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT03854994Phase 1
- Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell LymphomaStatus unknownNCT03853044Phase 2
- Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE StudyTerminatedNCT03850171Not applicable
- Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma PatientsWithdrawnNCT03850028Not applicable
- Self-Management and Activation to Reduce Treatment-Related Toxicities (SMARTCare)TerminatedNCT03849950Not applicable
- DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
- PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR StudyTerminatedNCT03837457Phase 2
- BTK Inhibitor DTRMWXHS-12 in Mantle Cell LymphomaCompletedNCT03836768Phase 1
- A Study of AG-636 in the Treatment of Subjects With Advanced LymphomaTerminatedNCT03834584Phase 1
- A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
- Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell LymphomaStatus unknownNCT03824964Early Phase 1
- Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell LymphomaStatus unknownNCT03824951Early Phase 1
- Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic LeukemiaStatus unknownNCT03823365Phase 1
- Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or LymphomaStatus unknownNCT03821363Phase 1
- RPTR-147 in Patients With Selected Solid Tumors and LymphomasTerminatedNCT03815682Phase 1
- Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaCompletedNCT03811457Not applicable
- A Study of CS1003 in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT03809767Phase 1
- Study of TG-1801 in Subjects With B-Cell LymphomaCompletedNCT03804996Phase 1
- The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
- Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaCompletedNCT03802955Phase 1
- Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell LymphomaCompletedNCT03798314Phase 1
- A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesTerminatedNCT03797261Phase 1
- Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell LymphomaStatus unknownNCT03797170
- Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCLStatus unknownNCT03795571Phase 1
- An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About CancerActive, not recruitingNCT03794635Not applicable
- BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's LymphomaCompletedNCT03794167Phase 2
- A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk TranslocationsCompletedNCT03793140Phase 2
- Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)CompletedNCT03792815Phase 2
- Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell TherapyStatus unknownNCT03790891Early Phase 1
- Vaccination With Flt3L, Radiation, and Poly-ICLCCompletedNCT03789097Phase 1/2
- MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell OriginStatus unknownNCT03778619Phase 1/2
- Study of Cosibelimab in Subjects With Relapsed or Refractory LymphomaTerminatedNCT03778073Phase 1
- Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03777085Phase 3
- A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell LymphomaStatus unknownNCT03776279Phase 2
- Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast CancerStatus unknownNCT03775525Phase 1
- A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)WithdrawnNCT03772288Phase 1
- Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaCompletedNCT03770416Phase 2
- Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HLCompletedNCT03766516
- Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic LeukemiaTerminatedNCT03755154Phase 1
- Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related FatigueActive, not recruitingNCT03747757Phase 2
- ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT03742921
- Study Of Intratumoral G100 In Cutaneous T Cell LymphomaWithdrawnNCT03742804Phase 2
- Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced MalignanciesCompletedNCT03739931Phase 1
- Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerWithdrawnNCT03739606Phase 2
- KN046 in Subjects With Advanced Solid Tumors and LymphomaCompletedNCT03733951Phase 1
- BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCTStatus unknownNCT03733327Phase 2/3
- GR1405 Injection in Patients With Advanced Solid Tumor or LymphomaStatus unknownNCT03731390Phase 1
- Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell LymphomaStatus unknownNCT03730740Phase 2
- Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin LymphomaCompletedNCT03730363Phase 1
- A Study of WXFL10030390 in Patients With Advanced Solid Tumors or LymphomaCompletedNCT03730142Phase 1
- Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced MalignanciesSuspendedNCT03722186Phase 1
- A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin LymphomaCompletedNCT03722147Phase 1/2
- Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell TherapyStatus unknownNCT03720496Phase 1
- Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.Status unknownNCT03720457Phase 1
- Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaStatus unknownNCT03719989Phase 2
- Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT03719898Phase 2
- Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell LymphomaWithdrawnNCT03719560Phase 2
- R2 in the Treatment of Follicular LymphomaStatus unknownNCT03715309Phase 2
- Lenalidomide Based Immunotherapy in the Treatment of DLBCLStatus unknownNCT03715296
- Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaActive, not recruitingNCT03712202Phase 2
- Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCLStatus unknownNCT03707847Phase 4
- Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaCompletedNCT03707093Phase 1
- Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaSuspendedNCT03704714Phase 1/2
- PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell LymphomaStatus unknownNCT03701022Phase 2